IgE binds omalizumab

Stable Identifier
R-HSA-9724685
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

When bound to the high-affinity IgE receptor (FCERI), IgE acts as an environmental sensor that detects allergens and induces allergic responses from the cell's interior. Omalizumab is a monoclonal antibody that binds free IgE preventing it from binding to FCERI. Moreover, reduction of free IgE concentrations reduce FCERI expression level. Omalizumab is approved for the treatment of patients with severe allergic asthma. Use of omalizumab is associated with several side effects, including injection site reactions, viral and upper respiratory tract infections, headache, sinusitis, and pharyngitis. The main severe adverse effect is anaphylactic shock, with a rate of occurrence of 1 to 2 patients per 1,000 (Davydov 2005, Arm et al. 2014).

Literature References
PubMed ID Title Journal Year
15686303 Omalizumab (Xolair) for treatment of asthma

Davydov, L

Am Fam Physician 2005
25200415 Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

Maahs, S, Floch, D, Bottoli, I, Lowe, PJ, Owen, CE, Groenewegen, A, Skerjanec, A, Jones, I, Arm, JP

Clin. Exp. Allergy 2014
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!